Published in Br J Cancer on March 01, 1991
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 1.83
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol (2003) 1.32
c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer (1991) 1.30
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25
Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol (2001) 1.23
p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer (1992) 1.19
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer (1995) 0.95
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer (1992) 0.91
The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother (2011) 0.88
Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer (1993) 0.86
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol (2006) 0.83
c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer (1992) 0.80
Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study. Medicine (Baltimore) (2015) 0.80
Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution study. J Korean Med Sci (2011) 0.79
Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer. Br J Cancer (1993) 0.79
Relationship between parameters from virtual touch tissue quantification (VTQ) imaging with clinicopathologic prognostic factors in women with invasive ductal breast cancer. Int J Clin Exp Pathol (2014) 0.77
Minimal breast cancer: evaluation of histology and biological marker expression. Br J Cancer (1999) 0.75
Biological indices in the assessment of breast cancer. Clin Mol Pathol (1995) 0.75
Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer. Med J Armed Forces India (2011) 0.75
Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br J Cancer (1994) 0.75
Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature. Breast Cancer (Dove Med Press) (2011) 0.75
Correlating Tumor Stiffness with Immunohistochemical Subtypes of Breast Cancers: Prognostic Value of Comb-Push Ultrasound Shear Elastography for Differentiating Luminal Subtypes. PLoS One (2016) 0.75
Gene therapy for carcinoma of the breast: Genetic toxins. Breast Cancer Res (1999) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A (1987) 3.64
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene (1987) 2.67
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J (1988) 2.59
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet (1987) 2.44
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell (1989) 2.30
Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci U S A (1987) 2.02
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res (1987) 1.70
Neu receptor dimerization. Nature (1989) 1.58
Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res (1989) 1.58
Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci U S A (1989) 1.58
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A (1986) 1.56
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer (1988) 1.52
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene (1989) 1.25
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer (1989) 1.23
The neu (c-erbB-2) oncogene. Semin Oncol (1989) 1.15
Breast cancer and a proto-oncogene. BMJ (1989) 1.13
Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res (1988) 1.10
Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol (1987) 1.07
The significance of oncogene amplification in primary breast cancer. Int J Cancer (1989) 1.06
Cellular and molecular aspects of neoplastic progression in the mammary gland. Eur J Cancer Clin Oncol (1988) 1.01
Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes (1987) 1.00
Amplification and over-expression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol (1988) 0.86
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet (2005) 7.25
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80
The reliability of Cancer Registry records. Br J Cancer (1993) 3.70
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med (1999) 2.76
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology (1992) 2.75
Polygenic susceptibility in rheumatoid arthritis. Ann Rheum Dis (1991) 2.66
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
The effect of feeding with a tryptophan-free amino acid mixture on rat-liver polysomes and ribosomal ribonucleic acid. Biochem J (1966) 2.53
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Return to work after inguinal hernia repair. Br J Surg (1993) 2.50
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet (1987) 2.44
The human transmissible spongiform encephalopathies (TSEs): implications for dental practitioners. Br Dent J (2000) 2.41
The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. Br J Cancer (1982) 2.39
Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res (1986) 2.38
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res (1993) 2.35
Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry (2001) 2.34
Methadone dosage and retention of patients in maintenance treatment. Med J Aust (1991) 2.31
The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J (1991) 2.30
Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med (2001) 2.30
Psychological and social evaluation in cases of deliberate self-poisoning seen in an accident department. Br Med J (Clin Res Ed) (1982) 2.29
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet (1999) 2.27
Leukemia following Hodgkin's disease. N Engl J Med (1990) 2.25
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Structure-function relationships in the collagenase family member transin. J Biol Chem (1988) 2.15
Linkage of COL1A2 collagen gene to cystic fibrosis, and its clinical implications. Lancet (1985) 2.14
In vitro mutational analysis of cis-acting RNA translational elements within the poliovirus type 2 5' untranslated region. J Virol (1991) 2.08
Purification and characterization of vaccinia virus growth factor. Cell (1985) 2.06
Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol (1988) 2.06
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Doctors detected self-administering opioids in New South Wales, 1985-1994: characteristics and outcomes. Med J Aust (1998) 2.04
Contributions of community involvement to organizational-level empowerment: the federal Healthy Start experience. Health Educ Behav (2001) 2.03
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94
Disease in children infected with HIV in Abidjan, Côte d'Ivoire. BMJ (1996) 1.92
Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology (1995) 1.90
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Reading the prognosis of the individual with breast cancer. Eur J Cancer (2007) 1.83
The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol (2000) 1.82
Effect of intravenous streptokinase on early mortality in patients with suspected acute myocardial infarction. A meta-analysis by anatomic location of infarction . Ann Intern Med (1990) 1.82
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82